PHAGE DISPLAY AFFINITY SELECTIONS

Affinity Selections

We understand that each project is unique and tailor each affinity selection to its specific needs. We begin with gaining in-depth knowledge of your target to design a customized biopanning strategy. Our unique multi-tiered approach yields peptides and antibodies with high binding affinity and optimal pharmacokinetics.

LETS TALK

Unlock the Possibilities of Phage Display!

Phage display technology is a widely adopted technique that allows the selection of peptides and antibodies from immense libraries of filamentous bacteriophage. This groundbreaking approach has demonstrated successful peptide- and antibody- targeting of diverse cancers, tissues, biomarkers, and even non-biological antigens. Previously, peptides and monoclonal antibodies were typically identified through in vitro phage display affinity selections (biopanning) against purified antigens such as recombinant proteins. However, while these selections deliver ligands with high affinity, their in vivo pharmacokinetic profile and target specificity often prove subpar. At Cell Origins, we address this challenge with our multi-tier phage display platform, consistently generating peptides and antibodies with exceptional binding affinity and pharmacokinetic properties.

Customizable Solutions

Our scientists are renowned experts in phage display technology. They are fully committed to providing you with exceptional biopanning strategies to discover high-affinity ligands that bind with specificity to your target of choice. Our team of experts stays on top of the latest advancements to empower your drug discovery projects.

Our team works directly with you to develop a customized phage display protocol that is tailored to meet your individual needs and requirements for peptide and antibody discovery services. We always perform an in-depth research analysis of your target molecule and/or tissue to ensure that we fully understand each challenge and how to solve it. We use multi-tier phage display methods combined with the latest automated high-throughput screening and sequencing technologies to ensure that each strategy results in quality peptides and antibodies that perform both in vitro and in vivo.

Target Antigens

We work with any type of target antigen to carry out phage display selections in vitro, in situ, and in vivo. Examples of target antigens include (but are not limited to):

In vitro

Purified recombinant/native proteins
Crude recombinant/native proteins
Oligo- and polysaccharides
Nucleic acids
Non-biological materials

In situ

Cell lines
Organoids
Tissues
Organs

In vivo

Mouse and rat models
Tumor tissues in live animals
Pre-clearing of phage display libraries

High-Affinity Ligands

Our dedicated scientists are committed to delivering high-affinity peptides and antibodies that specifically bind to your antigen. Utilizing customized protocols for each project, we employ meticulous biopanning methods, leveraging in vitro, in situ, and in vivo phage display selections. These approaches are tailored with precision elution and competition strategies, resulting in the identification of ligands with exceptional affinity and minimal off-target binding.

Optimal Pharmacokinetics

Finding ligands with high binding affinity and specificity for the target, while demonstrating excellent pharmacokinetics, poses a significant challenge in phage display antibody and peptide discovery. This challenge is amplified when examining intricate biological processes that are challenging to replicate in vitro and involve different binding partners based on tissue expression, a common occurrence in normal versus tumor tissues. To conquer this obstacle, we employ a multi-tier approach, enabling the concurrent selection of peptides and antibodies that possess the desired characteristics of high binding affinity, specificity, and pharmacokinetics. Our strategies are meticulously designed to yield ligands with increased stability, minimal off-target binding, and the necessary excretion profile. By doing so, we expedite the process of converting a hit into a lead molecule, ultimately saving you valuable time.

Our Expertise in Phage Display Technology

Our team of scientists are renowned experts in the field of phage display technology, continuously pushing the boundaries and exploring new frontiers with this powerful and versatile tool. With decades of experience and a passion for helping researchers achieve their goals, our scientists are dedicated to providing the latest innovative approaches.

Trained at the University of Missouri, the very birthplace of phage display, our lead scientists have not only honed their expertise but have also contributed significantly to the field. Their research articles have among others been cited by Dr. George Smith in his Nobel Prize lecture.

The scientists at Cell Origins have a background in developing cancer- and other disease-targeting peptides for therapy and imaging, kit development, and have in-depth knowledge of molecular biology and biochemistry. Additionally, we carry out projects in the fields of antibody discovery, development of functional and bioactive peptides, as well as peptides that bind non-biological antigens that must be stable under harsh conditions.

We are dedicated to supporting you throughout your entire journey of peptide or antibody discovery. By understanding your unique challenges and obstacles, we offer in-depth research analysis and a tailored project strategy. As the phage display biopanning takes place in our cutting-edge laboratories, we provide you with comprehensive reports that empower you to make informed decisions in transforming your hits into leads.

Contact Us to Learn More

Cell Origins is at the forefront of utilizing advanced multi-tier phage display techniques. Our groundbreaking work involves the development of peptides and monoclonal antibodies with exceptional binding kinetics and pharmacokinetics. Through our innovative multi-tier platform, lead compounds maintain high binding affinity, specificity, and optimal pharmacokinetics, while minimizing off-target binding. We invite you to reach out and discover how our unique phage display strategies can accelerate your drug discovery journey.

Let's Get Started!

At Cell Origins, we collaborate closely with you to create a customized affinity selection strategy that we carry out in our laboratories. Each biopanning protocol is tailored to your unique objectives. Our dedicated team of experts utilizes our multi-tiered approach to enable the identification of peptides and antibodies with exceptional binding kinetics and pharmacokinetics. We utilize proven affinity selection strategies combined with in-depth DNA and bioinformatic analyses to ensure that the selection of hit molecules is rooted in rigorous data. Throughout the phage display affinity selection, our team provides continuous project updates and comprehensive support. Whether you prefer to schedule a meeting or reach out to us directly, we are eager to learn more about your research needs.

LETS TALK

Published Work

Axiak-Bechtel, S. M., Leach, S. B., Scholten, D. G., Newton-Northup, J. R., Johnson, B. J., Durham, H. E., Gruber, K. A., Callahan, M. F. (2021). Pharmacokinetics and safety of TCMCB07, a melanocortin-4 antagonist peptide in dogs. Pharmacology Research & Perspectives. Vol. 9(3)

Asar, M., Franco, A., Soendergaard, M. (2020). Phage Display Selection, Identification, and Characterization of Novel Pancreatic Cancer Targeting Peptides. Biomolecules. 10(5), 714

Asar, M., Gunby, T., Franco, A., Woodson, C., Soendergaard, Mette. (2020). Identification of an Indiscriminate Peptide by Phage Display Technology. The FASEB Journal 34:1_supplement, 1-1
More

Asar, M., Newton-Northup, J., Deutscher, S., Soendergaard, M. (2019). Ovarian Cancer Targeting Phage for In Vivo Near-Infrared Optical Imaging. Diagnostics, 9, 183.

Newton-Northup, J.R., and Deutscher, S.L. (2017). Bacteriophage for the Development of Novel Tumor-Targeting Agents with Specific Pharmacokinetics and Imaging Applications. Methods in Molecular Biology in Biosensors and Biodetection.

Newton-Northup, J.R., and Deutscher, S.L.. (2016). Cytotoxic Tumor-Targeting Peptides From In Vivo Phage Display. Combinatorial Chemistry & High Throughput Screening. Vol. 19(5): 370–377

García, M. F., Zhang, X., Shah, M., Newton-Northup, J., Cabral, P., Cerecetto, H., and Quinn, T. (2016). 99mTc-bioorthogonal click chemistry reagent for in vivo pretargeted imaging. Bioorganic & Medicinal Chemistry. Vol. 24(6): 1209–1215

Newton-Northup, J.R., Dickerson, M.T., Kumar, S.R., Smith, G.P., Quinn, T.P., And Deutscher, S.L. (2014) In vivo bacteriophage peptide display to tailor pharmacokinetics of biological nanoparticles. Molecular Imaging and Biology. 16(6), 854-864.

Soendergaard M., Newton-Northup J. R., Deutscher S. L. (2014): In Vivo Phage Display Selection of an Ovarian Cancer Targeting Peptide for SPECT/CT Imaging. American Journal of Nuclear Medicine and Molecular Imaging. 4(6): 561–570.

Soendergaard, M., Newton-Northup, J.R., and Deutscher, S.L. (2014) In vitro high throughput phage display selection of ovarian cancer avid phage clones for near-infrared optical imaging. Combinatorial Chemistry and High Throughput Screening. 17(10).

Newton-Northup, J.R., and Deutscher, S.L. (2013). Contending With Target Unrelated Peptides from Phage Display. Journal of Molecular Imaging & Dynamics. Vol. 2(2):

Newton-Northup, J. R., Dickerson, M. T., Ma, L., Besch-Williford, C. L., Deutscher, S. L. (2013). Inhibition of metastatic tumor formation in vivo by a bacteriophage display-derived galectin-3 targeting peptide. Clinical & Experimental Metastasis. Vol. 30:119–132

Newton-Northup, J.R., and Deutscher, S.L. (2012) Contending with target unrelated peptides from phage display. Journal of Molecular Imaging and Dynamics. 2(2).

Soendergaard, M., Newton-Northup, J.R., Palmier, M.O., and Deutscher, S.L. (2011) Peptide phage display for discovery of novel biomarkers for imaging and therapy of cell subpopulations in ovarian cancer. Journal of Molecular Biomarkers and Diagnosis, S:2.

Newton-Northup, J.R., Figueroa, S.D., and Deutscher, S.L. (2010). Streamlined in vivo selection and screening of human prostate carcinoma avid phage particles for development of peptide based in vivo tumor imaging agents. Combinatorial chemistry & high throughput screening. 14(1):9-21

Deutscher, S. L., Dickerson, M., Gui, G., Newton, J., Holm, J. E., Vogeltanz-Holm, N., Kliethermes, B., Hewett, J. E., Kumar, S. R., Quinn, T. P., Sauter, E. R. (2010). Carbohydrate antigens in nipple aspirate fluid predict the presence of atypia and cancer in women requiring diagnostic breast biopsy. BMC Cancer. Vol. 10(519)

Newton-Northup, J.R., Figueroa, S.D., Quinn, T. P., and Deutscher, S.L. (2009). Bifunctional phage-based pretargeted imaging of human prostate carcinoma. Nuclear Medicine and Biology. Vol. 36(7):789-800

Jin, X., Newton, J. R., Montgomery, S., Smith, G. P. (2009). A generalized kinetic model for amine modification of proteins with application to phage display. Biotechniques. Vol. 46(3):175-182

Newton-Northup, J.R., and Deutscher, S.L. (2009). In vivo bacteriophage display for the discovery of novel peptide-based tumor-targeting agents. Methods in Molecular Biology. Vol. 504:275-90.

Newton-Northup, J.R., and Deutscher, S.L. (2008). Peptide Phage Display. Handbook of Experimental Pharmacology: Molecular Imaging I. Vol. 185 Pt 2:145-163.

Newton, J. R., Miao, Yubin., Deutscher, S. L., and Quinn, T. P. (2007). Melanoma Imaging with Pretargeted Bivalent Bacteriophage. Journal of Nuclear Medicine. Vol. 48(3):429-436

Newton, J. R., Kelly, K. A., Mahmood, U., Weissleder, R., and Deutscher, S. L. (2006) In vivo selection of phage for the optical imaging of PC-3 human prostate carcinoma in mice. Neoplasia. 8(9), 772-780.